Effect of rurality and travel distance on contralateral prophylactic mastectomy for unilateral breast cancer.
Contralateral prophylactic mastectomy
Rurality
Travel distance
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
04
11
2022
accepted:
29
03
2023
medline:
1
12
2023
pubmed:
25
4
2023
entrez:
24
04
2023
Statut:
ppublish
Résumé
Despite lack of survival benefit, demand for contralateral prophylactic mastectomy (CPM) to treat unilateral breast cancer remains high. High uptake of CPM has been demonstrated in Midwestern rural women. Greater travel distance for surgical treatment is associated with CPM. Our objective was to examine the relationship between rurality and travel distance to surgery with CPM. Women diagnosed with stages I-III unilateral breast cancer between 2007 and 2017 were identified using the National Cancer Database. Logistic regression was used to model likelihood of CPM based on rurality, proximity to metropolitan centers, and travel distance. A multinomial logistic regression model compared factors associated with CPM with reconstruction versus other surgical options. Both rurality (OR 1.10, 95% CI 1.06-1.15 for non-metro/rural vs. metro) and travel distance (OR 1.37, 95% CI 1.33-1.41 for those who traveled 50 + miles vs. < 30 miles) were independently associated with CPM. For women who traveled 30 + miles, odds of receiving CPM were highest for non-metro/rural women (OR 1.33 for 30-49 miles, OR 1.57 for 50 + miles; reference: metro women traveling < 30 miles). Non-metro/rural women who received reconstruction were more likely to undergo CPM regardless of travel distance (ORs 1.11-1.21). Both metro and metro-adjacent women who received reconstruction were more likely to undergo CPM only if they traveled 30 + miles (ORs 1.24-1.30). The impact of travel distance on likelihood of CPM varies by patient rurality and receipt of reconstruction. Further research is needed to understand how patient residence, travel burden, and geographic access to comprehensive cancer care services, including reconstruction, influence patient decisions regarding surgery.
Identifiants
pubmed: 37095280
doi: 10.1007/s10552-023-01689-9
pii: 10.1007/s10552-023-01689-9
pmc: PMC10689552
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-186Subventions
Organisme : NCCDPHP CDC HHS
ID : U48 DP006377
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA217797
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006401
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : ACL HHS
ID : U48DP006399
Pays : United States
Organisme : NIH HHS
ID : NIH T32 CA148062
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006400
Pays : United States
Organisme : NIMHD NIH HHS
ID : NIMHD K23 MD015719-01
Pays : United States
Organisme : NIMHD NIH HHS
ID : K23 MD015719
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA148062
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800012I
Pays : United States
Organisme : ACL HHS
ID : U48DP006401
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800012I/HHSN26100001
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP006389
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Ann Surg Oncol. 2017 Oct;24(10):2957-2964
pubmed: 28766231
Geospat Health. 2018 May 07;13(1):622
pubmed: 29772881
Plast Reconstr Surg. 2016 Jan;137(1):12-18
pubmed: 26710002
J Am Coll Surg. 2015 Jul;221(1):187-96
pubmed: 26047763
Ann Surg Oncol. 2014 Oct;21(10):3231-9
pubmed: 25081341
Health Serv Res. 2022 Jun;57(3):693-702
pubmed: 35146771
J Cancer Epidemiol. 2011;2011:107497
pubmed: 22496688
JAMA Surg. 2014 Jun;149(6):582-9
pubmed: 24849045
Gynecol Oncol Rep. 2021 Sep 25;38:100868
pubmed: 34692967
JAMA Surg. 2017 Jul 1;152(7):658-664
pubmed: 28384687
J Clin Oncol. 2015 Oct 1;33(28):3177-85
pubmed: 26304878
Transl Behav Med. 2020 May 20;10(2):355-363
pubmed: 30608607
Patient Educ Couns. 2007 Feb;65(2):158-65
pubmed: 16870385
Breast. 2018 Aug;40:156-164
pubmed: 29857282
Ann Surg Oncol. 2020 Jun;27(6):1805-1815
pubmed: 32206955
J Womens Health (Larchmt). 2020 Feb;29(2):220-229
pubmed: 30759049
Cancer Causes Control. 2013 Aug;24(8):1481-90
pubmed: 23677333
Plast Reconstr Surg. 2016 Jul;138(1):29-40
pubmed: 27348637
Ann Surg Oncol. 2021 Dec;28(13):8752-8765
pubmed: 34251554
Ann Surg. 2018 Feb;267(2):271-279
pubmed: 28594745
Ann Med Surg (Lond). 2020 Jun 23;56:95-107
pubmed: 32637082
Ann Surg Oncol. 2017 Oct;24(10):3038-3047
pubmed: 28766225
Ann Surg. 2017 Mar;265(3):581-589
pubmed: 28169929
N Engl J Med. 2018 Feb 1;378(5):473-479
pubmed: 29385378
Ann Surg Oncol. 2016 Oct;23(10):3100-5
pubmed: 27469117
MMWR Surveill Summ. 2017 Jul 07;66(14):1-13
pubmed: 28683054
Cancer Med. 2020 May;9(9):3088-3096
pubmed: 32159280
Psychooncology. 2018 Jun;27(6):1524-1529
pubmed: 29476578
J Clin Oncol. 2009 Sep 1;27(25):4177-81
pubmed: 19636004
Ann Surg Oncol. 2017 Jan;24(1):91-99
pubmed: 27654108
Ann Surg Oncol. 2017 Feb;24(2):375-397
pubmed: 27933411
J Surg Res. 2021 Jun;262:71-84
pubmed: 33548676
JAMA Surg. 2017 Mar 1;152(3):274-282
pubmed: 28002555
JAMA Surg. 2017 Jul 1;152(7):648-657
pubmed: 28355431
Ann Intern Med. 2013 Sep 17;159(6):373-81
pubmed: 24042365
JAMA Oncol. 2017 Dec 1;3(12):1722-1728
pubmed: 28241198
J Clin Oncol. 2018 Sep 1;36(25):2630-2638
pubmed: 30044695
Am J Surg. 2019 Jul;218(1):170-174
pubmed: 30554666
Cancer. 2017 Dec 1;123(23):4547-4555
pubmed: 28810062
Breast Cancer Res Treat. 2021 Jul;188(1):191-202
pubmed: 33582888